LON:FBT First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Share Price, News & Analysis GBX 2,331 -11.00 (-0.47%) As of 07:19 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsBuy This Stock About First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock (LON:FBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FBT alerts:Sign Up Key Stats Today's Range 2,331▼ 2,354.5050-Day Range 1,840.40▼ 2,358.5052-Week Range 1,451.20▼ 2,361.50Volume885 shsAverage Volume3,594 shsMarket Capitalization£956.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content. The company operates under the brand name of Blackbird. The company was founded in 1998 and is based in London, the United Kingdom. Read More Receive FBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBT Stock News HeadlinesBiotech could be one of 2026’s biggest winners, and this ETF is perfectly positionedJanuary 9, 2026 | msn.comFirst Trust NYSE Arca Biotechnology UCITS ETFApril 19, 2025 | barrons.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 8 at 1:00 AM | Profits Run (Ad)Amundi NYSE Arca Gold BUGS UCITS ETF USDApril 10, 2025 | barrons.comNet Asset Values(s)April 22, 2024 | finance.yahoo.comNet Asset Value(s)January 22, 2024 | finance.yahoo.comFirst Trust Energy Infr: Dividend InsightsSeptember 27, 2023 | benzinga.comLyxor NYSE Arca Gold BUGS (DR) UCITS ETF (CD91)May 11, 2023 | uk.investing.comSee More Headlines FBT Stock Analysis - Frequently Asked Questions How have FBT shares performed this year? First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's stock was trading at GBX 1,912.86 on January 1st, 2026. Since then, FBT shares have increased by 21.9% and is now trading at GBX 2,331. How do I buy shares of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation? Shares of FBT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation own? Based on aggregate information from My MarketBeat watchlists, some other companies that First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation investors own include Taylor Wimpey (TW), ARK Genomic Revolution ETF (ARKG), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Gold.com (GOLD) and Intel (INTC). Industry, Sector and Symbol Stock ExchangeLON SectorComputer and Technology Industry Software - Application Sub-IndustryN/A Current SymbolLON:FBT CIKN/A Webwww.forbidden.co.uk Phone+44-20-88797245FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick Ratio9.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares41,021,495Free FloatN/AMarket Cap£956.21 million OptionableNot Optionable Beta0.49 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:FBT) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredExecutive Order 14156 Is Set to Unleash TrillionsExecutive Order 14156 may be the most significant policy move in over 150 years — and most investors haven't t...Monument Traders Alliance | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
